Revenue Update on EXACT Sciences Corporation(NASDAQ:EXAS)

EXACT Sciences Corporation(NASDAQ:EXAS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 26, 2016. Company reported revenue of $21.18M. Analysts estimated a revenue of $18.54M. Earnings per share were $-0.46. Analysts had estimated an EPS of $-0.55.

In a different note, On Jun 16, 2016, Craig-Hallum said it Upgrades its rating on EXACT Sciences Corporation. The shares have been rated ‘Buy’ by the firm. On May 4, 2016, Mizuho Securities said it Downgrades its rating on EXACT Sciences Corporation. The shares have been rated ‘Neutral’ by the firm.

EXACT Sciences Corporation (EXAS) made into the market gainers list on Fridays trading session with the shares advancing 0.35% or 0.06 points. Due to strong positive momentum, the stock ended at $17.38, which is also near the day’s high of $17.64. The stock began the session at $17.31 and the volume stood at 45,15,159 shares. The 52-week high of the shares is $25 and the 52 week low is $4.67. The company has a current market capitalization of $1,709 M and it has 9,83,32,529 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 5, 2016, D Scott Coward (SVP and General Counsel) sold 1,644 shares at $12.28 per share price.Also, On Mar 11, 2016, Maneesh Arora (COO) sold 4,042 shares at $6.05 per share price.On Mar 11, 2016, Graham Peter Lidgard (Chief Science Officer) sold 3,041 shares at $6.05 per share price, according to the Form-4 filing with the securities and exchange commission.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers its test includes a protein marker to detect blood in the stool utilizing an antibody?based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre?cancerous lesions or polyps and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test affected patients can be referred to colonoscopy during which the polyps or lesions can be removed. The company’s test also detects blood in stool utilizing an antibody based FIT test.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *